PSMD5

Summary

PSMD5 (proteasome 26S subunit, non-ATPase 5, HGNC:9563) is a protein-coding gene on chromosome 9q33.2, encoding 26S proteasome non-ATPase regulatory subunit 5 (Q16401). Acts as a chaperone during the assembly of the 26S proteasome, specifically of the base subcomplex of the PA700/19S regulatory complex (RC).

The 26S proteasome is a multicatalytic proteinase complex with a highly ordered structure composed of 2 complexes, a 20S core and a 19S regulator. The 20S core is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. The 19S regulator is composed of a base, which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which contains up to 10 non-ATPase subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. This gene encodes a non-ATPase subunit of the 19S regulator base that functions as a chaperone protein during 26S proteasome assembly.

Source: NCBI Gene 5711 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 75 total
• Druggable target: yes
• MANE Select transcript: NM_005047

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9563
Approved symbol	PSMD5
Name	proteasome 26S subunit, non-ATPase 5
Location	9q33.2
Locus type	gene with protein product
Status	Approved
Aliases	S5B, KIAA0072
Ensembl gene	ENSG00000095261
Ensembl biotype	protein_coding
OMIM	604452
Entrez	5711

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 3 retained_intron, 1 nonsense_mediated_decay

ENST00000210313, ENST00000373903, ENST00000373904, ENST00000373920, ENST00000471789, ENST00000476949, ENST00000496688, ENST00000625444, ENST00000899083, ENST00000963400

RefSeq mRNA: 2 — MANE Select: NM_005047 NM_001270427, NM_005047

CCDS: CCDS59143, CCDS6824

Canonical transcript exons

ENST00000210313 — 10 exons

Exon	Start	End
ENSE00001656052	120829099	120829208
ENSE00001664782	120826765	120826907
ENSE00001680614	120821355	120821464
ENSE00001714724	120820839	120820979
ENSE00001724122	120824494	120824685
ENSE00001749259	120831331	120831459
ENSE00001853489	120816053	120818163
ENSE00001896328	120842737	120842922
ENSE00003466325	120833312	120833456
ENSE00003648374	120831832	120831945

Expression profiles

Bgee: expression breadth ubiquitous, 291 present calls, max score 94.26.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.0077 / max 165.8884, expressed in 1780 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
102304	11.0077	1780

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
hair follicle	UBERON:0002073	94.26	gold quality
esophagus squamous epithelium	UBERON:0006920	92.39	gold quality
tongue squamous epithelium	UBERON:0006919	91.84	gold quality
tibia	UBERON:0000979	91.72	gold quality
epithelium of esophagus	UBERON:0001976	91.51	gold quality
squamous epithelium	UBERON:0006914	90.30	gold quality
epithelium of mammary gland	UBERON:0003244	89.44	gold quality
mammary duct	UBERON:0001765	89.07	gold quality
islet of Langerhans	UBERON:0000006	89.03	gold quality
calcaneal tendon	UBERON:0003701	89.03	gold quality
oviduct epithelium	UBERON:0004804	89.03	gold quality
secondary oocyte	CL:0000655	88.95	gold quality
periodontal ligament	UBERON:0008266	88.91	gold quality
lower lobe of lung	UBERON:0008949	88.89	gold quality
gingiva	UBERON:0001828	88.77	gold quality
thoracic mammary gland	UBERON:0005200	88.57	gold quality
mammary gland	UBERON:0001911	88.54	gold quality
upper arm skin	UBERON:0004263	88.54	gold quality
right adrenal gland	UBERON:0001233	88.51	gold quality
palpebral conjunctiva	UBERON:0001812	88.47	gold quality
left adrenal gland	UBERON:0001234	88.37	gold quality
gingival epithelium	UBERON:0001949	88.35	gold quality
endometrium	UBERON:0001295	88.33	gold quality
cauda epididymis	UBERON:0004360	88.33	gold quality
adrenal gland	UBERON:0002369	88.29	gold quality
upper leg skin	UBERON:0004262	88.18	gold quality
parietal pleura	UBERON:0002400	88.17	gold quality
descending thoracic aorta	UBERON:0002345	88.16	gold quality
right adrenal gland cortex	UBERON:0035827	88.16	gold quality
decidua	UBERON:0002450	87.93	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.72

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

85 targeting PSMD5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-545-3P	99.95	70.74	2783
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-6772-5P	99.94	67.01	577
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-4524A-3P	99.72	66.85	2406

Literature-anchored findings (GeneRIF, showing 2)

• the critical role of S5b/PSMD5 in negative regulation of proteasome by TNF-alpha/NFkappaB and provide insights into proteasome inhibition in human disease. (PMID:22921402)
• Study in HT-29 cells and mouse colorectal tumor models revealed that levels of the proteasome assembly inhibitor PSMD5/S5B are significantly decreased in tumors, and re-expression of PSMD5 blocks 26S proteasome assembly. These results suggest that intestinal cancer cells escape proteotoxic stress by reducing PSMD5 to stimulate 26S proteasome assembly. (PMID:29716915)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	psmd5	ENSDARG00000059046
mus_musculus	Psmd5	ENSMUSG00000026869
rattus_norvegicus	Psmd5	ENSRNOG00000018809
drosophila_melanogaster	CG12096	FBGN0030457
caenorhabditis_elegans		WBGENE00009445

Protein

Protein identifiers

26S proteasome non-ATPase regulatory subunit 5 — Q16401 (reviewed: Q16401)

Alternative names: 26S protease subunit S5 basic, 26S proteasome subunit S5B

All UniProt accessions (3): Q16401, F2Z3J2, Q4VXH0

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a chaperone during the assembly of the 26S proteasome, specifically of the base subcomplex of the PA700/19S regulatory complex (RC). In the initial step of the base subcomplex assembly is part of an intermediate PSMD5:PSMC2:PSMC1:PSMD2 module which probably assembles with a PSMD10:PSMC4:PSMC5:PAAF1 module followed by dissociation of PSMD5.

Subunit / interactions. Interacts with PSMC1, PSMC2, PSMD1 and PSMD6. Part of transient complex containing PSMD5, PSMC2, PSMC1 and PSMD2 formed during the assembly of the 26S proteasome.

Domain organisation. Rich in dileucine repeats, which have been implicated in trafficking of a variety of transmembrane proteins.

Similarity. Belongs to the proteasome subunit S5B/HSM3 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q16401-1	1	yes
Q16401-2	2

RefSeq proteins (2): NP_001257356, NP_005038* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011989	ARM-like	Homologous_superfamily
IPR016024	ARM-type_fold	Homologous_superfamily
IPR019538	PSMD5	Family

Pfam: PF10508

UniProt features (6 total): sequence variant 2, initiator methionine 1, chain 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q16401-F1	93.96	0.89

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9907900	Proteasome assembly

MSigDB gene sets: 114 (showing top): GOBP_PROTEASOME_ASSEMBLY, LINDGREN_BLADDER_CANCER_CLUSTER_2A_DN, WANG_LMO4_TARGETS_DN, DOUGLAS_BMI1_TARGETS_DN, DANG_BOUND_BY_MYC, GOCC_PROTEASOME_REGULATORY_PARTICLE_BASE_SUBCOMPLEX, MARSON_BOUND_BY_FOXP3_STIMULATED, BENPORATH_MYC_MAX_TARGETS, GOCC_PROTEASOME_ACCESSORY_COMPLEX, SWEET_LUNG_CANCER_KRAS_UP, CHENG_RESPONSE_TO_NICKEL_ACETATE, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, LINDGREN_BLADDER_CANCER_CLUSTER_1_UP, LEE_BMP2_TARGETS_DN, GOCC_PEPTIDASE_COMPLEX

GO Biological Process (2): proteasome regulatory particle assembly (GO:0070682), proteasome assembly (GO:0043248)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): proteasome complex (GO:0000502), cytosol (GO:0005829), proteasome accessory complex (GO:0022624), proteasome regulatory particle, base subcomplex (GO:0008540)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein-containing complex	2
proteasome assembly	1
protein-containing complex assembly	1
binding	1
intracellular protein-containing complex	1
endopeptidase complex	1
cytoplasm	1
cellular anatomical structure	1
proteasome complex	1
intracellular anatomical structure	1
proteasome regulatory particle	1

Protein interactions and networks

STRING

1260 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PSMD5	PSMD4	P55036	976
PSMD5	PSMC1	P49014	816
PSMD5	PSMD2	Q13200	793
PSMD5	PSMD7	P51665	779
PSMD5	PSMD11	O00231	770
PSMD5	LONP1	P36776	747
PSMD5	ADRM1	Q16186	746
PSMD5	PSMD1	Q99460	702
PSMD5	PSMC6	P49719	684
PSMD5	PSMD9	O00233	679
PSMD5	PSMD8	P48556	671
PSMD5	PSMD6	Q15008	665
PSMD5	PSMC4	P43686	626
PSMD5	UCHL5	Q9Y5K5	625
PSMD5	PSMC3	P17980	605

IntAct

112 interactions, top by confidence:

A	B	Type	Score
PSMD5	PSMC2	psi-mi:“MI:0915”(physical association)	0.960
PSMC2	PSMD5	psi-mi:“MI:0915”(physical association)	0.960
PSMD5	PSMC2	psi-mi:“MI:0914”(association)	0.960
PSMD5	PSMC2	psi-mi:“MI:0407”(direct interaction)	0.960
PSMC1	PSMD5	psi-mi:“MI:0915”(physical association)	0.940
PSMD5	PSMC1	psi-mi:“MI:0915”(physical association)	0.940
PSMC3	PSMD9	psi-mi:“MI:0914”(association)	0.940
KIFAP3	KIF3B	psi-mi:“MI:0914”(association)	0.900
PSMC1	PSMC2	psi-mi:“MI:0914”(association)	0.890
UCHL5	PSMD12	psi-mi:“MI:0914”(association)	0.840
PSMD10	PSMD11	psi-mi:“MI:0914”(association)	0.800
PSMD13	PSMD11	psi-mi:“MI:0914”(association)	0.750
PSMD4	PSMD11	psi-mi:“MI:0914”(association)	0.750
PSMD7	PSMD11	psi-mi:“MI:0914”(association)	0.730
PSMC5	PSMD11	psi-mi:“MI:0914”(association)	0.730

BioGRID (269): PSMD5 (Two-hybrid), PSMD5 (Two-hybrid), TFCP2 (Two-hybrid), PSMD5 (Two-hybrid), BAG1 (Co-fractionation), DIS3L2 (Co-fractionation), GCSH (Co-fractionation), LAMB1 (Co-fractionation), MCM3 (Co-fractionation), P4HA1 (Co-fractionation), PAAF1 (Co-fractionation), PFKL (Co-fractionation), PFKM (Co-fractionation), PSMA3 (Co-fractionation), PSMA4 (Co-fractionation)

ESM2 similar proteins: A0JMW2, A2VE70, A5WW24, A7E2Y6, B9EJR8, E0CZ22, E1BP36, E7FBU4, O35638, O43156, O70576, O75155, Q08AM6, Q0P5A6, Q0V9L1, Q16401, Q5IFJ8, Q5JTH9, Q5R6L5, Q5ZIW5, Q5ZKD5, Q66L58, Q68F38, Q6DCF2, Q6P5B0, Q6ZQ73, Q7TMY7, Q80W92, Q80WQ2, Q84ZC0, Q86Y56, Q8C0Y0, Q8K2V6, Q8NDA8, Q8WVM7, Q91V83, Q96T76, Q99M76, Q9BPX3, Q9D071

Diamond homologs: Q0P5A6, Q16401, Q5IFJ8, Q8BJY1

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 86 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Autodegradation of the E3 ubiquitin ligase COP1	14	65.2×	1e-20
Regulation of activated PAK-2p34 by proteasome mediated degradation	13	63.5×	6e-19
Regulation of ornithine decarboxylase (ODC)	13	62.0×	6e-19
Vpu mediated degradation of CD4	13	60.6×	6e-19
Ubiquitin-dependent degradation of Cyclin D	13	60.6×	6e-19
Cross-presentation of soluble exogenous antigens (endosomes)	13	57.9×	8e-19
Vif-mediated degradation of APOBEC3G	13	57.9×	8e-19
Proteasome assembly	16	57.2×	2e-22

GO biological processes:

GO term	Partners	Fold	FDR
proteasome-mediated ubiquitin-dependent protein catabolic process	16	11.8×	2e-10

Disease & clinical

Clinical variants and AI predictions

ClinVar

75 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	59
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1241 predictions. Top by Δscore:

Variant	Effect	Δscore
9:120820976:CAGG:C	acceptor_gain	1.0000
9:120820978:GG:G	acceptor_gain	1.0000
9:120820978:GGCTA:G	acceptor_loss	1.0000
9:120820979:GCTA:G	acceptor_loss	1.0000
9:120820980:C:CC	acceptor_gain	1.0000
9:120820980:C:CG	acceptor_loss	1.0000
9:120829205:TTAG:T	acceptor_gain	1.0000
9:120831461:T:C	acceptor_gain	1.0000
9:120831831:CCG:C	donor_gain	1.0000
9:120820834:CCT:C	donor_loss	0.9900
9:120820835:CT:C	donor_loss	0.9900
9:120820836:TA:T	donor_loss	0.9900
9:120820838:C:CT	donor_loss	0.9900
9:120820975:TCAGG:T	acceptor_gain	0.9900
9:120820976:CAGGC:C	acceptor_gain	0.9900
9:120820977:AGG:A	acceptor_gain	0.9900
9:120820983:C:CT	acceptor_gain	0.9900
9:120820984:A:T	acceptor_gain	0.9900
9:120826908:C:CC	acceptor_gain	0.9900
9:120829111:T:TA	donor_gain	0.9900
9:120829204:ATTAG:A	acceptor_gain	0.9900
9:120829206:TAG:T	acceptor_gain	0.9900
9:120829208:GC:G	acceptor_loss	0.9900
9:120829209:C:A	acceptor_loss	0.9900
9:120829209:C:CC	acceptor_gain	0.9900
9:120829214:A:AC	acceptor_gain	0.9900
9:120831324:ATCTT:A	donor_loss	0.9900
9:120831325:TCTTA:T	donor_loss	0.9900
9:120831326:CTTAC:C	donor_loss	0.9900
9:120831327:TTACC:T	donor_loss	0.9900

AlphaMissense

3256 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:120817959:C:G	G488R	0.996
9:120817959:C:T	G488R	0.996
9:120818145:A:G	W426R	0.996
9:120818145:A:T	W426R	0.996
9:120817958:C:T	G488E	0.995
9:120817959:C:A	G488W	0.995
9:120817979:A:G	L481P	0.995
9:120818033:A:G	L463P	0.993
9:120818045:A:G	L459P	0.993
9:120820937:A:G	W387R	0.993
9:120820937:A:T	W387R	0.993
9:120824518:C:G	G328R	0.993
9:120824518:C:T	G328R	0.993
9:120829207:A:G	L188P	0.993
9:120824532:C:T	G323E	0.992
9:120824533:C:G	G323R	0.992
9:120824533:C:T	G323R	0.992
9:120824556:G:T	A315D	0.992
9:120824661:A:G	L280P	0.992
9:120818053:T:A	K456N	0.991
9:120818053:T:G	K456N	0.991
9:120826848:A:G	L244P	0.991
9:120831347:C:G	R182P	0.991
9:120831459:C:G	A145P	0.989
9:120817958:C:A	G488V	0.988
9:120818143:C:A	W426C	0.988
9:120818143:C:G	W426C	0.988
9:120824547:G:T	T318K	0.988
9:120818156:G:T	A422E	0.987
9:120829112:C:G	D220H	0.987

dbSNP variants (sampled 300 via entrez): RS1000017057 (9:120826175 T>A), RS1000269805 (9:120818127 AC>A), RS1000390465 (9:120843569 G>A,C,T), RS1000419449 (9:120837451 C>T), RS1000534873 (9:120833104 T>A), RS1000591856 (9:120830030 G>A), RS1000731406 (9:120837496 C>A,T), RS1000787020 (9:120838950 A>T), RS1000825402 (9:120816503 G>A), RS1000996779 (9:120824303 C>A,T), RS1001054704 (9:120832343 G>C), RS1001075924 (9:120824119 A>AG), RS1001098222 (9:120825256 A>T), RS1001276257 (9:120817705 T>G), RS1001429870 (9:120826830 A>G)

Disease associations

OMIM: gene MIM:604452 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006259_41	Systolic blood pressure	6.000000e-10
GCST90020028_393	Hip circumference adjusted for BMI	6.000000e-09
GCST90020028_394	Hip circumference adjusted for BMI	2.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067067 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.31	Kd	0.486	nM	CHEMBL5653589
9.31	ED50	0.486	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149128: Binding affinity to human PSMD5 incubated for 45 mins by Kinobead based pull down assay	kd	0.0005	uM

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, affects expression	3
Cadmium Chloride	decreases expression, increases expression	2
triphenyl phosphate	affects expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	increases expression	1
1-nitropyrene	increases expression	1
di-n-butylphosphoric acid	affects expression	1
nickel acetate	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
nutlin 3	affects cotreatment, increases secretion	1
LDN 193189	decreases expression, affects cotreatment	1
bisphenol AF	increases expression	1
Sunitinib	increases expression	1
Acetaminophen	decreases expression	1
Dactinomycin	affects cotreatment, increases secretion	1
Dinitrochlorobenzene	affects binding	1
Doxorubicin	decreases expression	1
Ivermectin	decreases expression	1
Ketoconazole	increases expression	1
Lead	affects expression	1
Quercetin	decreases expression	1
Testosterone	decreases expression	1
Urethane	decreases expression	1
Valproic Acid	affects expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652170	Binding	Binding affinity to human PSMD5 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2CH	Abcam HeLa PSMD5 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.